Anvisa approves sale of Pfizer medicine in pharmacies to treat Covid

by

The collegiate board of Anvisa (National Health Surveillance Agency) approved, this Monday (21), the sale of the drug Paxlovid to pharmacies and private hospitals in the country. Produced by Pfizer, the drug to treat Covid-19 is already incorporated into the SUS (Single Health System).

The decision authorizes the supply of the drug to the pharmacy and its sale can only be carried out with a medical prescription.

Paxlovid had its emergency use approved in Brazil in March of this year. It is indicated for adults who are not using oxygenation, but who are at risk of developing into severe cases of Covid-19.

The medicine is composed of two antivirals: nirmatrelvir and ritonavir. It acts to reduce the activity of the 3LC enzyme, associated with viral replication of Sars-CoV-2. The result is control of virus replication in human cells.

According to Anvisa, the measure considered the current epidemiological scenario, with the circulation of new subvariants of omicron and the increase in cases of the disease in the country.

“The medicine must be dispensed exclusively by the pharmacist, and the user must be instructed that the medicine is for individual and exclusive use to the patient who underwent medical evaluation and who received the prescription”, said the agency, in a note.

You May Also Like

Recommended for you